- Home
- RVPHW vs VSH Comparison
RVPHW vs VSH Comparison
Compare RVPHW & VSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- VSH
- Stock Information
- Founded
- RVPHW 2018
- VSH 1962
- Country
- RVPHW United States
- VSH United States
- Employees
- RVPHW 15
- VSH N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- VSH Electrical Products
- Sector
- RVPHW Health Care
- VSH Technology
- Exchange
- RVPHW Nasdaq
- VSH Nasdaq
- Market Cap
- RVPHW N/A
- VSH N/A
- IPO Year
- RVPHW N/A
- VSH N/A
- Fundamental
- Price
- RVPHW $0.03
- VSH $15.93
- Analyst Decision
- RVPHW
- VSH Buy
- Analyst Count
- RVPHW 0
- VSH 3
- Target Price
- RVPHW N/A
- VSH $22.00
- AVG Volume (30 Days)
- RVPHW 22.4K
- VSH 2.1M
- Earning Date
- RVPHW 03-14-2025
- VSH 05-07-2025
- Dividend Yield
- RVPHW N/A
- VSH 2.56%
- EPS Growth
- RVPHW N/A
- VSH N/A
- EPS
- RVPHW N/A
- VSH N/A
- Revenue
- RVPHW N/A
- VSH $2,937,587,000.00
- Revenue This Year
- RVPHW N/A
- VSH $4.58
- Revenue Next Year
- RVPHW N/A
- VSH $8.79
- P/E Ratio
- RVPHW N/A
- VSH N/A
- Revenue Growth
- RVPHW N/A
- VSH N/A
- 52 Week Low
- RVPHW $0.13
- VSH $14.95
- 52 Week High
- RVPHW $0.15
- VSH $24.69
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- VSH 38.40
- Support Level
- RVPHW N/A
- VSH $16.74
- Resistance Level
- RVPHW N/A
- VSH $17.43
- Average True Range (ATR)
- RVPHW 0.00
- VSH 0.50
- MACD
- RVPHW 0.00
- VSH -0.14
- Stochastic Oscillator
- RVPHW 0.00
- VSH 28.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.